Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 6 | 2019 | 117 | 1.480 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2019 | 95 | 1.310 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 65 | 1.240 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 51 | 1.170 |
Why?
|
| Knee Joint | 2 | 2018 | 128 | 1.060 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2018 | 44 | 1.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 99 | 0.960 |
Why?
|
| Medicare | 5 | 2022 | 219 | 0.870 |
Why?
|
| Postoperative Complications | 7 | 2022 | 823 | 0.850 |
Why?
|
| Neoplasms | 4 | 2022 | 754 | 0.840 |
Why?
|
| Humans | 41 | 2024 | 32282 | 0.830 |
Why?
|
| Orthopedics | 2 | 2023 | 93 | 0.830 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 762 | 0.700 |
Why?
|
| Case-Control Studies | 7 | 2022 | 854 | 0.690 |
Why?
|
| Retrospective Studies | 13 | 2024 | 3626 | 0.670 |
Why?
|
| Osteosarcoma | 2 | 2019 | 11 | 0.640 |
Why?
|
| United States | 11 | 2023 | 4072 | 0.640 |
Why?
|
| Aged | 16 | 2022 | 10263 | 0.630 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 520 | 0.620 |
Why?
|
| Osteoporosis | 1 | 2020 | 51 | 0.610 |
Why?
|
| Hemophilia B | 1 | 2019 | 6 | 0.610 |
Why?
|
| Shoulder Joint | 1 | 2022 | 139 | 0.600 |
Why?
|
| Hemophilia A | 1 | 2019 | 22 | 0.600 |
Why?
|
| Sarcoma | 3 | 2018 | 92 | 0.580 |
Why?
|
| Middle Aged | 18 | 2024 | 11851 | 0.580 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 56 | 0.570 |
Why?
|
| Teaching | 1 | 2019 | 60 | 0.560 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 131 | 0.540 |
Why?
|
| Ascorbic Acid | 1 | 2018 | 21 | 0.540 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 12 | 0.540 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 33 | 0.530 |
Why?
|
| Hip Fractures | 1 | 2017 | 26 | 0.530 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 3900 | 0.530 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 183 | 0.520 |
Why?
|
| Nutritional Status | 1 | 2017 | 73 | 0.510 |
Why?
|
| Antioxidants | 1 | 2018 | 122 | 0.510 |
Why?
|
| Patient Readmission | 1 | 2017 | 135 | 0.490 |
Why?
|
| Fractures, Bone | 1 | 2017 | 142 | 0.480 |
Why?
|
| Spasm | 1 | 2016 | 6 | 0.470 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 7 | 0.470 |
Why?
|
| Male | 18 | 2024 | 19441 | 0.460 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 33 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 381 | 0.430 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 489 | 0.420 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 73 | 0.420 |
Why?
|
| Angiotensin I | 1 | 2016 | 237 | 0.410 |
Why?
|
| Peptide Fragments | 1 | 2016 | 415 | 0.380 |
Why?
|
| Vascular Malformations | 1 | 2012 | 11 | 0.370 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 9 | 0.370 |
Why?
|
| Diphosphonates | 1 | 2012 | 9 | 0.360 |
Why?
|
| Alendronate | 1 | 2012 | 10 | 0.360 |
Why?
|
| Female | 16 | 2024 | 19945 | 0.360 |
Why?
|
| Risk Assessment | 1 | 2017 | 1425 | 0.360 |
Why?
|
| Fractures, Stress | 1 | 2012 | 10 | 0.360 |
Why?
|
| Brachytherapy | 1 | 2012 | 31 | 0.360 |
Why?
|
| Femoral Fractures | 1 | 2012 | 43 | 0.350 |
Why?
|
| Catheter Ablation | 1 | 2012 | 113 | 0.350 |
Why?
|
| Cephalosporins | 1 | 2021 | 8 | 0.340 |
Why?
|
| Carbapenems | 1 | 2021 | 7 | 0.340 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 30 | 0.340 |
Why?
|
| Wound Healing | 1 | 2021 | 185 | 0.310 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 46 | 0.310 |
Why?
|
| Fasting | 1 | 2020 | 88 | 0.310 |
Why?
|
| Dyslipidemias | 1 | 2020 | 60 | 0.300 |
Why?
|
| Regenerative Medicine | 1 | 2021 | 217 | 0.280 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 24 | 0.270 |
Why?
|
| Secondary Prevention | 2 | 2020 | 73 | 0.260 |
Why?
|
| Adult | 9 | 2024 | 9259 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3416 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 390 | 0.250 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 19 | 0.250 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 34 | 0.250 |
Why?
|
| Animals | 6 | 2022 | 8199 | 0.240 |
Why?
|
| Dystonia | 1 | 2015 | 7 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Risk Factors | 3 | 2020 | 3934 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Length of Stay | 2 | 2017 | 321 | 0.200 |
Why?
|
| Reoperation | 2 | 2022 | 252 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Bone Density Conservation Agents | 2 | 2020 | 23 | 0.190 |
Why?
|
| Hypertension | 1 | 2020 | 979 | 0.190 |
Why?
|
| Comorbidity | 3 | 2022 | 565 | 0.190 |
Why?
|
| Obesity | 1 | 2020 | 1111 | 0.190 |
Why?
|
| Tissue Scaffolds | 2 | 2021 | 431 | 0.190 |
Why?
|
| Employment | 1 | 2023 | 44 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1158 | 0.180 |
Why?
|
| Physicians | 1 | 2024 | 163 | 0.180 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 51 | 0.170 |
Why?
|
| Medicaid | 1 | 2022 | 101 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 11 | 0.170 |
Why?
|
| Mice | 3 | 2022 | 2571 | 0.170 |
Why?
|
| Patient Care Team | 2 | 2017 | 124 | 0.160 |
Why?
|
| Papillomaviridae | 1 | 2020 | 23 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 907 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 65 | 0.160 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 55 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 79 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 97 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1083 | 0.150 |
Why?
|
| Knee Prosthesis | 1 | 2019 | 18 | 0.150 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 109 | 0.150 |
Why?
|
| Osteoblastoma | 1 | 2019 | 1 | 0.150 |
Why?
|
| Prosthesis-Related Infections | 1 | 2019 | 31 | 0.150 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2019 | 2 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 38 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2022 | 242 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 43 | 0.150 |
Why?
|
| Blood Transfusion | 1 | 2019 | 69 | 0.150 |
Why?
|
| Comprehension | 1 | 2019 | 19 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 137 | 0.150 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2018 | 5 | 0.140 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2018 | 6 | 0.140 |
Why?
|
| Sarcoma, Synovial | 1 | 2018 | 6 | 0.140 |
Why?
|
| Neurilemmoma | 1 | 2018 | 17 | 0.140 |
Why?
|
| Gout | 1 | 2018 | 13 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 24 | 0.140 |
Why?
|
| Emotions | 1 | 2019 | 54 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 37 | 0.140 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 14 | 0.140 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 69 | 0.140 |
Why?
|
| Matched-Pair Analysis | 1 | 2017 | 11 | 0.130 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 165 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 11 | 0.130 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2018 | 24 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 2017 | 7 | 0.130 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 10 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 19 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 40 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2017 | 95 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 106 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 169 | 0.130 |
Why?
|
| Osteomyelitis | 1 | 2017 | 26 | 0.130 |
Why?
|
| Hand | 1 | 2017 | 79 | 0.130 |
Why?
|
| Osteoarthritis | 1 | 2017 | 73 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 456 | 0.120 |
Why?
|
| Bone Density | 1 | 2018 | 169 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2018 | 188 | 0.120 |
Why?
|
| Arthroscopy | 1 | 2018 | 242 | 0.120 |
Why?
|
| Acrospiroma | 1 | 2016 | 4 | 0.120 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 8 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 651 | 0.120 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 55 | 0.120 |
Why?
|
| Hindlimb | 1 | 2016 | 53 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 95 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 743 | 0.110 |
Why?
|
| Reference Values | 1 | 2016 | 238 | 0.110 |
Why?
|
| Fibrosis | 1 | 2016 | 126 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2022 | 461 | 0.110 |
Why?
|
| Random Allocation | 1 | 2016 | 247 | 0.110 |
Why?
|
| Carcinoma | 1 | 2016 | 92 | 0.110 |
Why?
|
| Bone Nails | 1 | 2015 | 39 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2016 | 471 | 0.110 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2015 | 40 | 0.110 |
Why?
|
| Bone Plates | 1 | 2015 | 71 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 556 | 0.110 |
Why?
|
| Radius Fractures | 1 | 2015 | 68 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 591 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 545 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2015 | 137 | 0.100 |
Why?
|
| Joint Instability | 1 | 2015 | 89 | 0.100 |
Why?
|
| Young Adult | 3 | 2019 | 2649 | 0.100 |
Why?
|
| Phlebography | 1 | 2012 | 26 | 0.090 |
Why?
|
| Veins | 1 | 2012 | 34 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 94 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 12 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2022 | 113 | 0.090 |
Why?
|
| Wound Infection | 1 | 2012 | 12 | 0.090 |
Why?
|
| Adolescent | 3 | 2019 | 3519 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 36 | 0.090 |
Why?
|
| Imidazoles | 1 | 2012 | 97 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 109 | 0.090 |
Why?
|
| Epithelium | 1 | 2021 | 22 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2021 | 8 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 363 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 555 | 0.080 |
Why?
|
| Ketone Bodies | 1 | 2020 | 7 | 0.080 |
Why?
|
| Mutation | 1 | 2022 | 497 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 117 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 368 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2020 | 255 | 0.070 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2018 | 19 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2018 | 21 | 0.070 |
Why?
|
| Hospitalization | 2 | 2022 | 475 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2018 | 91 | 0.060 |
Why?
|
| Child | 2 | 2019 | 2435 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2022 | 1840 | 0.060 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 6 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 1224 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 62 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2018 | 413 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2017 | 171 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 77 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2018 | 603 | 0.060 |
Why?
|
| Professional Misconduct | 1 | 2024 | 3 | 0.050 |
Why?
|
| Medicine | 1 | 2024 | 36 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 1179 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2022 | 84 | 0.040 |
Why?
|
| Lumbosacral Region | 1 | 2021 | 12 | 0.040 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 1 | 0.040 |
Why?
|
| Germinal Center | 1 | 2020 | 6 | 0.040 |
Why?
|
| Laminectomy | 1 | 2021 | 14 | 0.040 |
Why?
|
| Diskectomy | 1 | 2021 | 17 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 14 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2020 | 12 | 0.040 |
Why?
|
| Spinal Fusion | 1 | 2021 | 52 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 89 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 129 | 0.040 |
Why?
|
| Bone Substitutes | 1 | 2019 | 9 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 70 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sclerosis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2019 | 79 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 228 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 157 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 114 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 245 | 0.040 |
Why?
|
| Bone Cements | 1 | 2018 | 10 | 0.040 |
Why?
|
| Curettage | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 454 | 0.040 |
Why?
|
| Tibia | 1 | 2018 | 56 | 0.030 |
Why?
|
| Bone Transplantation | 1 | 2018 | 51 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 76 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 79 | 0.030 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2017 | 2 | 0.030 |
Why?
|
| Itraconazole | 1 | 2017 | 6 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 388 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 53 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 272 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2017 | 45 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 72 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 792 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 116 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 757 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 883 | 0.030 |
Why?
|
| Fractures, Closed | 1 | 2015 | 9 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 44 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 293 | 0.030 |
Why?
|
| Wrist Joint | 1 | 2015 | 57 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 504 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 196 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 242 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 695 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 410 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 199 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 252 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2240 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 2316 | 0.020 |
Why?
|